An open-label study of escitalopram (Lexapro®) for the treatment of 'depression of Alzheimer's disease' (dAD)

Vani A Rao, J. R. Spiro, Paul B Rosenberg, H. B. Lee, A. Rosenblatt, Constantine G Lyketsos

Research output: Contribution to journalArticle

Abstract

Background: Depression is a frequent neuropsychiatric complication of Alzheimer's Disease. Methods: This study investigated the safety and effectiveness of escitalopram (LEXAPRO) for depression in AD (dAD) as defined by the NIMH consensus criteria in an 8-week, open-label treatment study. Conclusion: Escitalopram was efficacious and safe for the treatment of dAD in this study. Larger, controlled studies are warranted to further assess the efficacy for mood and behavioral disturbances in this medically fragile population.

Original languageEnglish (US)
Pages (from-to)273-274
Number of pages2
JournalInternational Journal of Geriatric Psychiatry
Volume21
Issue number3
DOIs
StatePublished - Mar 2006

Fingerprint

Citalopram
Alzheimer Disease
Depression
National Institute of Mental Health (U.S.)
Consensus
Safety
Population

Keywords

  • Depression in Alzheimer's disease
  • Escitalopram

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Psychiatry and Mental health

Cite this

An open-label study of escitalopram (Lexapro®) for the treatment of 'depression of Alzheimer's disease' (dAD). / Rao, Vani A; Spiro, J. R.; Rosenberg, Paul B; Lee, H. B.; Rosenblatt, A.; Lyketsos, Constantine G.

In: International Journal of Geriatric Psychiatry, Vol. 21, No. 3, 03.2006, p. 273-274.

Research output: Contribution to journalArticle

@article{7ca50a26ff43443da56745f1ba9e2dfb,
title = "An open-label study of escitalopram (Lexapro{\circledR}) for the treatment of 'depression of Alzheimer's disease' (dAD)",
abstract = "Background: Depression is a frequent neuropsychiatric complication of Alzheimer's Disease. Methods: This study investigated the safety and effectiveness of escitalopram (LEXAPRO) for depression in AD (dAD) as defined by the NIMH consensus criteria in an 8-week, open-label treatment study. Conclusion: Escitalopram was efficacious and safe for the treatment of dAD in this study. Larger, controlled studies are warranted to further assess the efficacy for mood and behavioral disturbances in this medically fragile population.",
keywords = "Depression in Alzheimer's disease, Escitalopram",
author = "Rao, {Vani A} and Spiro, {J. R.} and Rosenberg, {Paul B} and Lee, {H. B.} and A. Rosenblatt and Lyketsos, {Constantine G}",
year = "2006",
month = "3",
doi = "10.1002/gps.1459",
language = "English (US)",
volume = "21",
pages = "273--274",
journal = "International Journal of Geriatric Psychiatry",
issn = "0885-6230",
publisher = "John Wiley and Sons Ltd",
number = "3",

}

TY - JOUR

T1 - An open-label study of escitalopram (Lexapro®) for the treatment of 'depression of Alzheimer's disease' (dAD)

AU - Rao, Vani A

AU - Spiro, J. R.

AU - Rosenberg, Paul B

AU - Lee, H. B.

AU - Rosenblatt, A.

AU - Lyketsos, Constantine G

PY - 2006/3

Y1 - 2006/3

N2 - Background: Depression is a frequent neuropsychiatric complication of Alzheimer's Disease. Methods: This study investigated the safety and effectiveness of escitalopram (LEXAPRO) for depression in AD (dAD) as defined by the NIMH consensus criteria in an 8-week, open-label treatment study. Conclusion: Escitalopram was efficacious and safe for the treatment of dAD in this study. Larger, controlled studies are warranted to further assess the efficacy for mood and behavioral disturbances in this medically fragile population.

AB - Background: Depression is a frequent neuropsychiatric complication of Alzheimer's Disease. Methods: This study investigated the safety and effectiveness of escitalopram (LEXAPRO) for depression in AD (dAD) as defined by the NIMH consensus criteria in an 8-week, open-label treatment study. Conclusion: Escitalopram was efficacious and safe for the treatment of dAD in this study. Larger, controlled studies are warranted to further assess the efficacy for mood and behavioral disturbances in this medically fragile population.

KW - Depression in Alzheimer's disease

KW - Escitalopram

UR - http://www.scopus.com/inward/record.url?scp=33645579430&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645579430&partnerID=8YFLogxK

U2 - 10.1002/gps.1459

DO - 10.1002/gps.1459

M3 - Article

C2 - 16477587

AN - SCOPUS:33645579430

VL - 21

SP - 273

EP - 274

JO - International Journal of Geriatric Psychiatry

JF - International Journal of Geriatric Psychiatry

SN - 0885-6230

IS - 3

ER -